Start Over

Clinical application of [ 18 F]FDG PET/CT in follicular lymphoma.

Authors :: Díaz-Silván A
Otón-Sánchez LF
Caresia-Aróztegui AP
Del Puig Cózar-Santiago M
Orcajo-Rincón J
de Arcocha-Torres M
Delgado-Bolton RC
Cabello-García D
Source :: Revista espanola de medicina nuclear e imagen molecular [Rev Esp Med Nucl Imagen Mol (Engl Ed)] 2022 May-Jun; Vol. 41 (3), pp. 202-212. Date of Electronic Publication: 2022 Apr 27.
Publication Year :: 2022
Abstract: The objective of the present paper was to review the clinical application of [ <superscript>18</superscript> F]FDG PET/CT in follicular lymphoma (FL). Once it was clear that, despite it is characterized as indolent, this type of lymphoma usually shows a high [ <superscript>18</superscript> F]FDG avidity, PET/CT became more important and it's now considered the standard technique in staging, re-staging and response evaluation. Many studies have shown its impact on the management of patients (as it can change the stage in a significant proportion of cases and lead to treatment modifications), its superiority over CT (mainly because it's able to distinguish fibrosis in residual masses from viable tumor) and its prognostic value. The latter was initially associated only to the degree of metabolic response, which has proved to be a strong and independent predictive factor in terms of disease-free survival (DFS) and overall survival (OS). Thus, a negative PET/CT scan could be considered a guarantee in high-tumor-burden follicular lymphoma patients. However, semiquantitative parameters such as metabolic tumor volume or total lesion glycolysis, may also provide useful information and help us to identify patients with poor prognosis, guiding a risk-adjusted management and follow-up.<br /> (Copyright © 2022 Sociedad Española de Medicina Nuclear e Imagen Molecular. Published by Elsevier España, S.L.U. All rights reserved.)